On 27 February 2017, orphan designation (EU/3/17/1831) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 505 amino acid protein, corresponding to amino acids 2-506 of the wild-type human histidyl-tRNA synthetase (also known as ATYR1940) for the treatment of limb-girdle muscular dystrophy.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in January 2020 on request of the Sponsor.
EU/3/17/1831: Public summary of opinion on orphan designation: 505 amino acid protein, corresponding to amino acids 2-506 of the wild-type human histidyl-tRNA synthetase for the treatment of limb-girdle muscular dystroph... (PDF/206.13 KB)
First published: 31/03/2017
Last updated: 31/03/2017
505 amino acid protein, corresponding to amino acids 2-506 of the wild-type human histidyl-tRNA synthetase
|Disease / condition||
Treatment of limb-girdle muscular dystrophy
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.